The Dutch genomics company Cergentis BV has appointed Joris Schuurmans as chief executive and Dirk Pollet and Maja Sanders as members of its supervisory board. Cergentis develops and commercialises technology for the diagnosis of cancer. Mr Schuurmans has extensive experience in the molecular diagnostics and biopharmaceutical industry and previously held senior positions at Biocartis SA and MyCartis NV. Dr Pollet is currently CEO of Enzyre BV. Ms Sanders currently holds supervisory roles at a number of non-profit organisations, and has a background in private equity.
Cergentis announced the appointments on 30 June 2020.
Copyright 2020 Evernow Publishing Ltd
